Daejeon, South Korea

Joon-Goo Jung

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 10.6

ph-index = 1

Forward Citations = 6(Granted Patents)


Location History:

  • Incheon, KR (2014)
  • Daejeon, KR (2012 - 2015)

Company Filing History:


Years Active: 2012-2015

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Joon-Goo Jung: Innovator in Anti-Inflammatory and Anticancer Research

Introduction

Joon-Goo Jung is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the fields of anti-inflammatory and anticancer research. With a total of 4 patents to his name, his work is recognized for its potential impact on medical treatments.

Latest Patents

Joon-Goo Jung's latest patents include innovative solutions for inflammatory diseases and cancer treatment. One of his notable inventions is an anti-inflammatory composition that utilizes an antibody specifically binding to CD93 or its soluble fragment. This invention also encompasses a diagnostic method and kit for inflammatory diseases using the CD93-specific antibody or aptamer. Another significant patent involves an anticancer drug that comprises an inhibitor of TMPRSS4, a transmembrane protease. This anticancer agent is designed to inhibit TMPRSS4 expression in cancer cells, effectively reducing cancer cell invasion and growth.

Career Highlights

Joon-Goo Jung is affiliated with the Korea Research Institute of Bioscience and Biotechnology, where he conducts his research. His work is characterized by a strong focus on developing therapeutic agents that address critical health issues.

Collaborations

Some of his notable coworkers include Young Woo Park and So-Young Choi, who contribute to the collaborative efforts in his research projects.

Conclusion

Joon-Goo Jung's innovative work in the fields of anti-inflammatory and anticancer research showcases his commitment to advancing medical science. His patents reflect a dedication to finding effective solutions for pressing health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…